KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biogen (BIIB) Revenue (2016 - 2025)

Biogen has reported Revenue over the past 17 years, most recently at $2.3 billion for Q4 2025.

  • Quarterly results put Revenue at $2.3 billion for Q4 2025, down 7.14% from a year ago — trailing twelve months through Dec 2025 was $9.9 billion (up 2.22% YoY), and the annual figure for FY2025 was $9.9 billion, up 2.22%.
  • Revenue for Q4 2025 was $2.3 billion at Biogen, down from $2.5 billion in the prior quarter.
  • Over the last five years, Revenue for BIIB hit a ceiling of $2.8 billion in Q3 2021 and a floor of $2.3 billion in Q4 2025.
  • Median Revenue over the past 5 years was $2.5 billion (2022), compared with a mean of $2.5 billion.
  • Biggest five-year swings in Revenue: fell 24.63% in 2021 and later rose 7.33% in 2025.
  • Biogen's Revenue stood at $2.7 billion in 2021, then decreased by 6.94% to $2.5 billion in 2022, then dropped by 6.2% to $2.4 billion in 2023, then increased by 2.87% to $2.5 billion in 2024, then fell by 7.14% to $2.3 billion in 2025.
  • The last three reported values for Revenue were $2.3 billion (Q4 2025), $2.5 billion (Q3 2025), and $2.6 billion (Q2 2025) per Business Quant data.